Search

Your search keyword '"MEROLA, B."' showing total 286 results
Start Over Author "MEROLA, B."
286 results on '"MEROLA, B."'

16. Intracellular Mechanisms in GH Control

Author

Schettini, G., Florio, T., Meucci, O., Landolfi, E., Grimaldi, M., Magri, G., Merola, B., Lombardi, G., Müller, Eugenio E., editor, MacLeod, Robert M., editor, Wass, John A. H., editor, and Scanlon, Maurice F., editor

Published
1989
Full Text
View/download PDF

19. Abnormal vascular reactivity in growth hormone deficiency

Author

CAPALDO, BRUNELLA, GUARDASOLE V. PARDO F, MATARAZZO M, DI RELLA F. NUMIS F, MEROLA B, LONGOBARDI S, SACC L., Capaldo, Brunella, GUARDASOLE V., PARDO F, Matarazzo, M, DI RELLA F., NUMIS F, Merola, B, Longobardi, S, and Sacc, L.

Published
2001

23. Growth hormone and heart performance. A novel mechanism ofcardiac wall stress regulation in humans

Author

Fazio S, Cittadini A, Sabatini D, Merola B, Colao A, BIONDI, BERNADETTE, Longobardi S, Lombardi G, Saccà L., Fazio, S, Cittadini, A, Sabatini, D, Merola, B, Colao, A, Biondi, Bernadette, Longobardi, S, Lombardi, G, and Saccà, L.

Abstract

OBJECTIVES: This study was designed to assess systolic wall stress and ventricular function in patients with deranged growth hormone secretion, in an attempt to elucidate the mechanisms of growth hormone interaction with heart performance. DESIGN: A case-control study. SUBJECTS: Thirty patients with active acromegaly, free of diabetes mellitus and coronary artery disease, and 25 subjects with congenital growth hormone deficiency were studied. Twelve growth hormone-deficient subjects were reevaluated after 12 months of recombinant human growth hormone therapy. Two groups of 30 normal subjects each were used as controls for the acromegalic and growth hormone-deficient patients, respectively. RESULTS: In the acromegalics, end-systolic wall stress was reduced (-20%; P < 0.01) due to ventricular wall thickening (+ 26%; P < 0.001), whereas cardiac output was significantly increased (+ 20%; P < 0.01). The velocity of fibre shortening was unchanged. In growth hormone-deficient subjects, end-systolic wall stress was markedly increased (+ 38%; P < 0.001) due to a significant reduction of ventricular wall thickness (- 28%; P < 0.001), whereas cardiac output was significantly decreased (-44%; P < 0.001). Replacement therapy with recombinant human growth hormone produced a partial correction of wall thickness and stress. Consequently, systolic performance and cardiac output improved significantly. CONCLUSION: This study demonstrates that growth hormone plays a role in the control of cardiac wall stress and performance through a mechanism mediated by the effect of growth hormone on myocardial tissue growth. The data may have therapeutic implications in cardiac diseases that lead to heart failure.

Published
1997

26. Cardiovascular aspects in acromegaly: effects of treatment

Author

Lombardi, G, Colao, A, Ferone, Diego, Marzullo, P, Landi, Ml, Longobardi, S, Iervolino, E, Cuocolo, A, Fazio, S, Merola, B., Lombardi, G., Colao, A., Ferone, D., Marzullo, P., Landi, M. L., Longobardi, S., Cuocolo, A., Fazio, Serafino, Merola, B., and Sacca', Luigi

Published
1996

28. Impaired cardiac performance is a distinct feature ofuncomplicated acromegaly

Author

Fazio S, Cittadini A, Cuocolo A, Merola B, Sabatini D, Colao A, Lombardi G, Saccà L., BIONDI, BERNADETTE, Fazio, S, Cittadini, A, Cuocolo, A, Merola, B, Sabatini, D, Colao, A, Biondi, Bernadette, Lombardi, G, and Saccã, L.

Subjects
Endocrinology, Endocrinology, Diabetes and Metabolism, Biochemistry (medical), Clinical Biochemistry, acromegaly, Biochemistry
Abstract

This study was designed to assess right and left ventricular function in patients with active acromegaly. To this end, 26 acromegalic patients (9 of whom had arterial hypertension) and 15 normal subjects of comparable age and sex distribution were studied by radionuclide angiography at rest and during supine bicycle-ergometer exercise and echocardiography. At rest, the filling rates of left (-19%; P < 0.005) and right ventricle (-32%; P < 0.001) were significantly reduced in acromegalic patients, whereas right and left ventricle ejection fractions (EFs) were normal. During physical exercise, EF was considerably lower in the acromegalic patients than in controls. This was true for both left, (61 +/- 11% us. 75 +/- 8%; P < 0.001) and right ventricle (45 +/- 13 vs. 58 +/- 11%; < 0.002). In as many as 73% of patients, EF increased less than 5%, thus fulfilling the criteria for impaired cardiac performance. Left ventricular mass index was 60% greater in acromegalics than in controls (P < 0.001). A significant difference in left ventricular mass index was also present when normotensive acromegalic patients were compared with controls (P < 0.001). No significant difference in the indices of systolic and diastolic function was observed between the subgroups of normotensive and hypertensive acromegalics, either at rest or during exercise. The data demonstrate that in uncomplicated acromegaly, besides cardiac hypertrophy, there are also important alterations of systolic and diastolic function of both ventricles, leading to a significant impairment of cardiac performance.

Published
1994

29. Ormone della crescita e cuore

Author

FAZIO S, SABATINI D, BIONDI B, MEROLA B, COLAO A, LOMBARDI G, SACCÁ L., CITTADINI, ANTONIO, Fazio, S, Sabatini, D, Cittadini, Antonio, Biondi, B, Merola, B, Colao, A, Lombardi, G, and Saccá, L.

Published
1994

31. Impairment of cardiac performance in adult growth-hormone deficiency

Author

CITTADINI, ANTONIO, CUOCOLO A, MEROLA B, FAZIO S, SABATINI D, NICOLAI E, COLAO A, LONGOBARDI S, LOMBARDI G, SACCÁ L., Cittadini, Antonio, Cuocolo, A, Merola, B, Fazio, S, Sabatini, D, Nicolai, E, Colao, A, Longobardi, S, Lombardi, G, and Saccá, L.

Published
1994

35. Effetti cardiaci del GH

Author

FAZIO S, SABATINI D, SANTOMAURO M, MEROLA B, BIONDI, BERNADETTE, COLAO A, LOMBARDI G, S.A.C.C.A.'.L., CITTADINI, ANTONIO, Fazio, S, Sabatini, D, Cittadini, Antonio, Santomauro, M, Merola, B, Biondi, Bernadette, Colao, A, Lombardi, G, and S. A. C. C. A. '., L.

Published
1993

36. Valutazione della funzione ventricolare sinistra in pazienti con acromegalia: studio radionuclidico

Author

IMBRIACO, MASSIMO, MAUREA, SIMONE, Cuocolo A, Nicolai E, Nappi A, Sullo P, Cardei S, Klain M, Cittadini A, Sabatini D, Colao A, Ferone D, BIONDI, BERNADETTE, Merola B, Fazio S, Squame G, Salvatore M., Imbriaco, Massimo, Cuocolo, A, Nicolai, E, Maurea, Simone, Nappi, A, Sullo, P, Cardei, S, Klain, M, Cittadini, A, Sabatini, D, Colao, A, Ferone, D, Biondi, Bernadette, Merola, B, Fazio, S, Squame, G, and Salvatore, M.

Published
1993

37. Valutazione ecocardiografica nel paziente adulto con deficit di GH

Author

LOMBARDI G, MEROLA B, COLAO A, LONGOBARDI S, ROSSI E, BIONDI, BERNADETTE, SABATINI D, FAZIO S., CITTADINI, ANTONIO, Lombardi, G, Merola, B, Colao, A, Longobardi, S, Rossi, E, Biondi, Bernadette, Cittadini, Antonio, Sabatini, D, and Fazio, S.

Published
1993

39. Ormone della crescita e cuore

Author

FAZIO, SERAFINO, SABATINI D., CITTADINI A., LOMBARDI G., MEROLA B., BIONDI, BERNADETTE, COLAO A., LONGOBARDI S., SACCÀ L., Fazio, Serafino, Sabatini, D., Cittadini, A., Lombardi, G., Merola, B., Biondi, Bernadette, Colao, A., Longobardi, S., and Saccà, L.

Published
1993

43. Cardiac muscle in adult patients affected with GH deficiency (AGHD)

Author

MEROLA B, ROSSI E, LONGOBARDI S, FERONE D, ESPOSITO V, COLAO A, FAZIO S, ORIO F, LOMBARDI G., CITTADINI, ANTONIO, Merola, B, Rossi, E, Longobardi, S, Ferone, D, Esposito, V, Colao, A, Cittadini, Antonio, Fazio, S, Orio, F, and Lombardi, G.

Published
1992

45. Heart and acromegaly

Author

MEROLA B, COLAO A, BIONDI B, CATALDI, MAURO, ROSSI E, FAZIO S, PICARDI G, SABATINI D, SACC L., CITTADINI, ANTONIO, Merola, B, Colao, A, Biondi, B, Cataldi, Mauro, Rossi, E, Fazio, S, Cittadini, Antonio, Picardi, G, Sabatini, D, and Sacc, L.

Published
1991

47. Efficacia del trattamento cronico con alendronato nell'osteoporosi della malattia di Cushing

Author

C Di Somma, Colao, A, Pivonello, R, Klain, M, Faggiano, A, S Tripodi, F, Merola, B, Salvatore, M, and Lombardi, G

Subjects
3) 8 patients with active disease treated with ketoconazole alone, when pituitary surgery was unsuccessful. Study design: Lumbar spine (L1-L4) and femoral neck BMD, in patients and controls, serum OC levels were lower (1.1 +/- 0.1 vs 1.5 +/- 0.1 nmol/l, urinary cross-linked N-telopeptides of type I collagen (Ntx) levels were evaluated at study entry, P < 0.05) and femoral neck (0.69 +/- 0.3 vs. 0.96 +/- 0.6 g/cm2, P < 0.01). In the alendronate-treated groups, serum OC levels increased, P < 0.01), a significant increase of serum OC levels and a significant decrease of Ntx levels were observed together with a slight increase of BMD values after 12 months. No significant change in either biochemical markers or BMD values was found in patients of group 3. Conclusions: Patients with Cushing's disease have osteoporosis which needs to be rapidly reversed to limit the risk of fracture. The results of the present study show that a 12 month treatment period with alendronate induced an improvement in bone mineral density greater than in untreated patients, serum osteocalcin (OC), 2) 11 patients with inactive disease treated with alendronate, and were repeated after 6 and 12 months in the 39 patients. Results: BMD values were lower in patients with Cushing's disease than in controls at both L1-L4 (0.72 +/- 0.4 vs. 1.01 +/- 0.6 g/cm2, Background: Osteoporosis is common in patients with Cushing's disease and is likely due to an imbalance between bone formation and resorption. Alendronate is an aminobisphosphonate that is able to increase bone mass mainly by inhibiting bone resorption. Objective: We have evaluated the effect of chronic treatment with alendronate on bone mineral density (BMD) in patients with Cushing's disease. Patients: 39 patients with Cushing's disease entered this study. 39 age-, sex- and BMI-matched normals served as controls for baseline evaluation. The 39 patients were divided into four groups: 1) 10 patients with active disease treated with alendronate and ketoconazole, 3) 8 patients with active disease treated with ketoconazole alone, 4) 10 patients with inactive disease received no treatment. Treatment protocol: Alendronate was given for 12 months in a dose of 10 mg orally once daily after fasting at 0800 h in the morning. Ketoconazole was given in a dose of 200-600 mg orally daily, when pituitary surgery was unsuccessful. Study design: Lumbar spine (L1-L4) and femoral neck BMD, serum osteocalcin (OC), urinary cross-linked N-telopeptides of type I collagen (Ntx) levels were evaluated at study entry, in patients and controls, and were repeated after 6 and 12 months in the 39 patients. Results: BMD values were lower in patients with Cushing's disease than in controls at both L1-L4 (0.72 +/- 0.4 vs. 1.01 +/- 0.6 g/cm2, P < 0.05) and femoral neck (0.69 +/- 0.3 vs. 0.96 +/- 0.6 g/cm2, P < 0.05). In the 39 patients with Cushing's disease considered as a whole, serum OC levels were lower (1.1 +/- 0.1 vs 1.5 +/- 0.1 nmol/l, P < 0.01), while Ntx values were higher than in controls (168 +/- 25 vs. 61 +/- 31 nmol BCE/mmol creatinine, P < 0.01). In the alendronate-treated groups, serum OC levels increased, while Ntx levels significantly decreased after 6 and 12 months of treatment without any significant difference between the two groups. BMD values measured at L1-L4 and femoral neck significantly increased after 12 months of therapy. In patients of group 4, a significant increase of serum OC levels and a significant decrease of Ntx levels were observed together with a slight increase of BMD values after 12 months. No significant change in either biochemical markers or BMD values was found in patients of group 3. Conclusions: Patients with Cushing's disease have osteoporosis which needs to be rapidly reversed to limit the risk of fracture. The results of the present study show that a 12 month treatment period with alendronate induced an improvement in bone mineral density greater than in untreated patients, sex- and BMI-matched normals served as controls for baseline evaluation. The 39 patients were divided into four groups: 1) 10 patients with active disease treated with alendronate and ketoconazole, P < 0.05). In the 39 patients with Cushing's disease considered as a whole, while Ntx values were higher than in controls (168 +/- 25 vs. 61 +/- 31 nmol BCE/mmol creatinine, Background: Osteoporosis is common in patients with Cushing's disease and is likely due to an imbalance between bone formation and resorption. Alendronate is an aminobisphosphonate that is able to increase bone mass mainly by inhibiting bone resorption. Objective: We have evaluated the effect of chronic treatment with alendronate on bone mineral density (BMD) in patients with Cushing's disease. Patients: 39 patients with Cushing's disease entered this study. 39 age, while Ntx levels significantly decreased after 6 and 12 months of treatment without any significant difference between the two groups. BMD values measured at L1-L4 and femoral neck significantly increased after 12 months of therapy. In patients of group 4, 4) 10 patients with inactive disease received no treatment. Treatment protocol: Alendronate was given for 12 months in a dose of 10 mg orally once daily after fasting at 0800 h in the morning. Ketoconazole was given in a dose of 200-600 mg orally daily
Published
1998

48. Correlation of scintigraphic results using I-123-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas

Author

Ferone, D, Lastoria, S, Colao, A, Varrella, P, Cerbone, GA, Acampa, W, Merola, B, Salvatore, M, and Lombardi, G

Abstract

The efficacy of dopaminergic agents in the medical treatment of pituitary adenomas is well known. Quinagolide is a nonergot derivative dopamine agonist, which binds dopamine D-2 receptors with high affinity. The treatment with this drug is reported to suppress hormone levels and to cause tumor shrinkage in prolactinomas and in a few GK-secreting pituitary adenomas. In clinically nonfunctioning pituitary adenomas (NFPA), the efficacy of quinagolide treatment is controversial. The scintigraphy of the pituitary region using I-123-methoxybenzamide (I-123-IBZM) allows US to visualize in vivo the expression of dopamine D-2 receptors on pituitary tumors. In this study, the pituitary scintigraphy with I-123-IBZM was performed in 14 patients with macroadenoma before starting a long-term treatment with quinagolide: 6 NFPA with high circulating alpha-subunit levels, 4 PRL-secreting, and 4 GH-secreting adenomas. A 3-point score was used to grade the ligand accumulation within the pituitary adenomas: 0 = negative, 1 = moderate uptake (equal to that recorded in the cerebral cortex), and 2 = intense uptake (equal to that recorded in the basal nuclei). The treatment with quinagolide was carried out at the dose of 0.3-0.6 mg/day for 6-12 months. Clinical, biochemical and hormonal assessment was repeated monthly during the first 3 months, then quarterly. Sellar magnetic resonance imaging was performed before and after 6 and 12 months of quinagolide treatment, to evaluate tumor shrinkage (>25% of baseline size).

Published
1998
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results